COO option exercise and share sale at Vaxcyte (PCVX) totals 2,250 shares
Rhea-AI Filing Summary
Vaxcyte, Inc. chief operating officer Jim Wassil exercised stock options for 2,250 shares of common stock at $5.35 per share on August 3, 2026, then sold a total of 2,250 shares in two transactions at weighted-average prices of $53.502 and $54.089 per share under a Rule 10b5-1 trading plan. The exercised options were fully vested and exercisable, and 68,898 stock options remained beneficially owned afterward. His reported direct holdings include 781 shares acquired through the company’s employee stock purchase plan on May 15, 2026.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Exercise and Sale: 2,250 shares ($109K approx. pre-tax spread)
Exercise and Sale
4 txns
Insider
Wassil Jim
Role
CHIEF OPERATING OFFICER
Sold
2,250 shs ($121K)
Approx. gross sale proceeds
$121K
Approx. exercise cost
$12K
Approx. pre-tax spread
$109K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (right to buy) F5 | 2,250 | $0.00 | $0.00 |
| Exercise | Common Stock F1 | 2,250 | $5.35 | $12K |
| Sale | Common Stock F2, F3 | 861 | $53.502 | $46K |
| Sale | Common Stock F2, F4 | 1,389 | $54.089 | $75K |
Holdings After Transaction:
Stock Option (right to buy) — 68,898 shares (Direct);
Common Stock — 157,541 shares (Direct)
Footnotes (5)
- F1. Includes 781 shares acquired under the Issuer's Employee Stock Purchase Plan on May 15, 2026.
- F2. The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on December 9, 2025.
- F3. The price reported is a weighted-average price. The shares were sold at prices ranging from $52.915 to $53.91. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- F4. The price reported is a weighted-average price. The shares were sold at prices ranging from $53.935 to $54.36. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- F5. Stock Option is fully vested and exercisable.
Key Figures
Options exercised: 2,250 shares
Exercise price: $5.35 per share
Shares sold tranche 1: 861 shares at $53.502 per share
+4 more
7 metrics
Options exercised
2,250 shares
Stock options converted into common stock on August 3, 2026
Exercise price
$5.35 per share
Price paid to exercise 2,250 stock options
Shares sold tranche 1
861 shares at $53.502 per share
First reported sale of common stock on August 3, 2026
Shares sold tranche 2
1,389 shares at $54.089 per share
Second reported sale of common stock on August 3, 2026
Total shares sold
2,250 shares
Combined common stock sales reported for August 3, 2026
Options remaining
68,898 shares
Stock options beneficially owned after the reported option exercise
ESPP shares
781 shares
Shares acquired under the Employee Stock Purchase Plan on May 15, 2026
Key Terms
Rule 10b5-1 trading plan, weighted-average price, Employee Stock Purchase Plan, Stock Option
4 terms
Rule 10b5-1 trading plan regulatory
"The sales were effected pursuant to a Rule 10b5-1 trading plan"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted-average price financial
"The price reported is a weighted-average price for the shares sold"
Weighted-average price is the average of multiple prices where each price is counted according to its size or importance—larger trades carry more weight than smaller ones, like averaging course grades by credit hours. It matters to investors because it gives a more realistic picture of the true price paid or received, helping assess trade execution, compare performance, calculate cost basis, and value positions more accurately than a simple average.
Employee Stock Purchase Plan financial
"Includes 781 shares acquired under the Issuer's Employee Stock Purchase Plan"
An employee stock purchase plan is a company program that lets workers buy shares through small payroll deductions, often at a discount to the market price and after a set offering period. Think of it like a workplace savings plan that turns into ownership: it encourages employees to share in the company’s success and can create predictable buying or selling of stock that investors watch because it affects supply, demand and employee incentives.
Stock Option financial
"Stock Option is fully vested and exercisable"
A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What insider transactions did Vaxcyte (PCVX) report for COO Jim Wassil?
Vaxcyte reported that COO Jim Wassil exercised 2,250 stock options at $5.35 per share and sold 2,250 common shares on August 3, 2026. The sales occurred in two tranches at weighted-average prices of $53.502 and $54.089 per share.
How many Vaxcyte (PCVX) stock options does the COO still hold after these trades?
After exercising 2,250 options, Jim Wassil beneficially owned 68,898 stock options. These options were reported as fully vested and exercisable, indicating they can be converted into Vaxcyte common shares according to their original terms and expiration schedule.
Were the Vaxcyte (PCVX) insider sales made under a Rule 10b5-1 plan?
Yes. The sales were effected under a Rule 10b5-1 trading plan, with the company indicating the plan was in place and a footnote stating it was adopted on December 9, 2025. Such plans pre-schedule trades to reduce discretion over timing.